SPRINT试验中肾小管功能标志物与心血管事件及死亡风险的关系
在SPRINT试验的2377例慢性肾病患者中,评估尿α1微球蛋白、β2微球蛋白和尿调节素与复合心血管事件及死亡的关系。中位随访3.8年,校正eGFR和蛋白尿后,α1微球蛋白升高与心血管事件和死亡风险增加相关,尿调节素升高与心血管事件风险降低相关。
要点
- 在非糖尿病慢性肾病患者中,肾小管功能标志物与心血管事件和死亡风险独立于肾小球功能和蛋白尿相关。
- α1微球蛋白浓度翻倍与心血管事件风险增加25%及死亡风险增加25%相关。
核心结论
- 在非糖尿病慢性肾病患者中,肾小管功能生物标志物与心血管事件和死亡风险相关,且独立于肾小球滤过功能和蛋白尿。
研究设计与样本
- 基于SPRINT试验基线2377例慢性肾病患者的样本分析,使用Cox比例风险回归模型评估三种尿肾小管功能标志物与复合心血管终点及死亡的关系,中位随访3.8年。
主要发现
- 未校正分析中,α1微球蛋白和β2微球蛋白与复合心血管事件和死亡风险呈正相关,尿调节素与两种结局风险呈负相关。
- 多变量分析中,基线α1微球蛋白浓度翻倍与心血管事件风险升高相关(HR 1.25;95%CI:1.10-1.45)及死亡风险升高相关(HR 1.25;95%CI:1.10-1.46)。
- 多变量分析中,β2微球蛋白与心血管事件或死亡均无显著关联。
- 多变量分析中,尿调节素浓度翻倍与心血管事件风险降低相关(HR 0.79;95%CI:0.68-0.90),但与死亡风险无显著关联(HR 0.86;95%CI:0.73-1.01)。
临床怎么用
- 在慢性肾病患者中,可考虑检测尿α1微球蛋白和尿调节素以辅助评估心血管事件和死亡风险,但需进一步验证。
局限性
- 研究样本为非糖尿病慢性肾病患者,结论外推至其他人群需谨慎。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Biomarkers of kidney tubule injury, inflammation and fibrosis have been studied extensively and established as risk markers of adverse kidney and cardiovascular disease (CVD) outcomes. However, associations of markers of kidney tubular function with adverse clinical events have not been well studied, especially in persons with chronic kidney disease (CKD). METHODS AND RESULTS: Using a sample of 2377 persons with CKD at the baseline Systolic Blood Pressure Intervention Trial (SPRINT) visit, we evaluated the association of three urine tubular function markers, alpha-1 microglobulin (α1m), beta-2 microglobulin (β2m), and uromodulin, with a composite CVD endpoint (myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes) and mortality using Cox proportional hazards regression, adjusted for baseline estimated glomerular filtration rate (eGFR), albuminuria, and CVD risk factors. In unadjusted analysis, over a median follow-up of 3.8 years, α1m and β2m had positive associations with composite CVD events and mortality, whereas uromodulin had an inverse association with risk for both outcomes. In multivariable analysis including eGFR and albuminuria, a two-fold higher baseline concentration of α1m was associated with higher risk of CVD [hazard ratio (HR) 1.25; 95% confidence interval (CI): 1.10-1.45] and mortality (HR 1.25; 95% CI: 1.10-1.46), whereas β2m had no association with either outcome. A two-fold higher uromodulin concentration was associated with lower CVD risk (HR 0.79; 95% CI: 0.68-0.90) but not mortality (HR 0.86; 95% CI: 0.73-1.01) after adjusting for similar confounders. CONCLUSION: Among non-diabetic persons with CKD, biomarkers of tubular function are associated with CVD events and mortality independent of glomerular function and albuminuria.
引用
- Garimella PS, Lee AK, Ambrosius WT, et al. Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial. Eur Heart J. 2019. PMID: 31257404. doi:10.1093/eurheartj/ehz392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。